Individuals using a widely prescribed blood pressure treatment are being urgently advised to inspect their pill packets after a significant packaging error was discovered. Health authorities have issued a critical alert concerning a specific batch of Ramipril, following reports that some boxes contain an incorrect dosage of the medication.
Precautionary Recall Announced
The Medicines and Healthcare Products Regulatory Agency (MHRA) has confirmed that this recall is a precautionary step to safeguard patient well-being. This action was prompted by a complaint where a pack of 5mg capsules was found inside a sealed carton clearly labelled as the 10mg version.
Details of the Error
The MHRA stated: "Crescent Pharma Limited is recalling one batch of Ramipril 10mg capsules as a precautionary measure due to a potential manufacturing error, which may mean some cartons contain blister strips of a lower dose, specifically Ramipril 5mg. This follows a complaint from a patient where it was identified that, inside a sealed carton of Ramipril 10mg capsules (Batch No.: GR174091), one blister pack of Ramipril 5mg capsules (Batch No.: GR164094) was found."
Immediate Actions Required
Pharmacists and doctors have been instructed to halt distribution of the affected stock and begin contacting anyone who may have purchased it recently. Patients prescribed this medication should carefully examine their current supply to ensure the capsules match the dosage indicated on the outer carton.
Health Risks and Advice
Dr Alison Cave, MHRA chief safety officer, explained that both strengths of Ramipril are used to treat conditions such as high blood pressure, heart failure, and kidney disease. She emphasized: "Any possible impact of a lower dose of Ramipril is expected to be gradual rather than immediate or life-threatening."
She further advised: "If you have an impacted pack or previously received this batch and you believe you have taken any Ramipril 5mg capsules that were included in error and are currently experiencing any adverse effects, please seek medical advice. Please take the leaflet that came with your medicine and any remaining tablets with you to your pharmacy or GP practice. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme."
Ongoing Efforts to Trace Medication
Health professionals are actively working to trace the medication distributed over the past year to minimize any potential risks to the public. The focus is particularly on identifying patients who received the supply recently, although much of the batch was released in 2025, according to reports.
This incident underscores the importance of vigilance in medication safety and the critical role of regulatory bodies in protecting public health. Patients are encouraged to stay informed and proactive in managing their prescriptions.
